Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

New technique shields patients from toxic parts of antibiotic drug

A new technique which targets antibiotic-resistant bacteria and shields patients from the toxic parts of an antibiotic drug has been developed by Cardiff University scientists.

8 Jul 2011

Baltimore symposium to discuss human factors and ergonomics in health-care

The Human Factors and Ergonomics Society invites you to attend the 2012 Symposium on Human Factors and Ergonomics in Health Care, to be held March 12-14, 2012, at the Marriott Baltimore Waterfront Hotel in Baltimore, Maryland. Mark your calendars for this exciting first-time event.

6 Jul 2011

Novel drug delivery device can treat diabetes-related retinal damage

A team of engineers and scientists at the University of British Columbia has developed a device that can be implanted behind the eye for controlled and on-demand release of drugs to treat retinal damage caused by diabetes.

1 Jul 2011

New book explores research into viral nanoparticles

Viruses that attack plants, insects, mammals and bacteria are proving effective platforms for delivering medicines and imaging chemicals to specific cells in the body, as building blocks for tiny battery electrodes and computer data storage devices, and other nanotechnologies.

1 Jul 2011

Cipher grants Vertical exclusive U.S. distribution rights to CIP-TRAMADOL ER

Cipher Pharmaceuticals Inc. today announced that it has entered into a definitive distribution and supply agreement with Vertical Pharmaceuticals, Inc., a U.S.-based specialty pharmaceutical company, under which Cipher has granted Vertical the exclusive right to market, sell and distribute CIP-TRAMADOL ER in the United States.

29 Jun 2011

A.P. Pharma enters into definitive agreements for $24M private placement of common stock and warrants

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that it has entered into definitive agreements with certain new and existing accredited investors providing for a private placement of common stock and warrants in which the Company will receive $24 million in gross proceeds.

29 Jun 2011

TrialNet presents Diamyd Phase II study results on type 1 diabetes at ADA 2011

The American research consortium Type 1 Diabetes TrialNet presented their results of a Phase II study with the antigen-based diabetes therapy Diamyd yesterday, June 27, at the American Diabetes Association 71st Scientific Sessions (ADA) in San Diego, California, USA, after the closing of the stock market.

28 Jun 2011

Australian Nobel Prize winner closer to delivering vaccines in food after positive first study in humans

The Australian scientist who won a Nobel Prize for identifying a cancer-causing stomach bacterium, today said a clinical trial had shown that some strains of the bacteria (Helicobacter pylori or H. pylori) were safe and well tolerated in humans.

27 Jun 2011

Cardium to purchase Transdel's business assets

Cardium Therapeutics today announced that it had entered into an agreement with Transdel Pharmaceuticals to acquire substantially all of Transdel's business assets including a Phase 3 product candidate Ketotransdel (TDLP-110), which is a topically-administered analgesic for the treatment of musculoskeletal pain.

27 Jun 2011

Flamel, Digna Biotech enter joint development agreement for multiple products

Flamel Technologies SA and Digna Biotech SL today announced that the two companies have entered into a joint development agreement for the pre-clinical and clinical development of multiple products.

27 Jun 2011

BD receives CEO Cancer Gold Standard accreditation

BD has received CEO Cancer Gold Standard accreditation, recognizing the company's commitment to reducing cancer risk by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment for its own employees and their covered family members.

From BD (Becton, Dickinson and Company) 27 Jun 2011

FDA accepts for filing Columbia's PROCHIEVE progesterone gel NDA

Columbia Laboratories, Inc. and Watson Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Columbia's New Drug Application (NDA) for PROCHIEVE (progesterone gel) for the reduction of risk of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy.

27 Jun 2011

Diabetic patients can benefit from basal insulin analogs

Basal insulin analogs have revolutionized diabetes care, and especially the treatment of type 2 diabetes, enabling patients to achieve better control of blood glucose levels while reducing hypoglycemic episodes.

27 Jun 2011

Department of Defense awards Impel Phase II SBIR grant for blood-brain barrier bypass technology

Impel NeuroPharma, a medical device company whose technology is designed to enable pharmaceutical drugs to bypass the blood-brain barrier and enter the central nervous system (CNS), today announced that it was selected to receive a Phase II Small Business Investigational Research (SBIR) grant from the Department of Defense's Chemical and Biological Defense SBIR Program entitled, "Blood Brain Barrier Drug Delivery of Therapeutics for Chemical Warfare Agents."

24 Jun 2011

Watson Pharmaceuticals expands Salt Lake City R&D and manufacturing facility

Watson Pharmaceuticals, Inc., today formally announced an approximately $44 million expansion of its Salt Lake City, Utah, Watson Laboratories, Inc. site.

23 Jun 2011

Positive results from Neurelis NRL-1 Phase I pharmacokinetic study on acute repetitive seizures

In a recent announcement by Neurelis, a proprietary intranasal formulation of diazepam achieved positive clinical results in a Phase I pharmacokinetic study.

23 Jun 2011

Diamyd Medical to terminate US DiaPrevent Phase III study for type 1 diabetes

Diamyd Medical AB reports that the Company has decided to suspend dosing in a US Phase III study with the antigen-based therapy Diamyd and to initiate closure of the study.

23 Jun 2011

Novel method of disguising nanoparticles as red blood cells to fight cancer

Researchers at the University of California, San Diego have developed a novel method of disguising nanoparticles as red blood cells, which will enable them to evade the body's immune system and deliver cancer-fighting drugs straight to a tumor. Their research was published this week in the online Early Edition of the Proceedings of the National Academy of Sciences.

22 Jun 2011

Halozyme to present three data on Ultrafast Insulin programs at ADA 2011

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced three upcoming data presentations for it Ultrafast Insulin programs at the American Diabetes Association (ADA) 71st Scientific Sessions taking place June 24-28, 2011 at the San Diego Convention Center.

21 Jun 2011

Wayne State team receives $330,000 NSF grant to develop 3-D neural probe for tinnitus

A team of Wayne State University researchers was awarded $330,000 from the National Science Foundation (NSF) to develop a 3-D neural probe. Their aim is to develop an implantable device that will suppress tinnitus, a neurological disorder that affects more than 250 million people worldwide.

21 Jun 2011